Foley attorneys filed an amicus brief in the United States District Court for the Southern District of New York related to ACLU v. Myriad regarding subject matter patentability of gene patents specifically on isolated DNA. The authors conclude that the U.S. Congress, U.S. courts and the USPTO, as well as the scientific community and biotechnology industry have long relied upon an understanding that claims directed to “isolated DNA” recite patentable subject matter under 35 U.S.C. §101 and the Constitution. The authors maintain that to hold otherwise would have a dramatic negative effect on biotech research as we know it, and will influence the entire business of biotechnology in ways unforeseen or addressed by the plaintiffs in ACLU v. Myriad”
People
Related News
July 14, 2025
Press Releases
Foley Adds Litigation Partner Matt Caplan in San Francisco, Strengthening Technology and Health Care Sector Capabilities
Foley & Lardner LLP announced today that Matt Caplan has joined the firm’s San Francisco office as a partner in its Commercial Litigation Practice Group and Innovative Technology and Health Care & Life Sciences Sectors.
July 8, 2025
Press Releases
Foley Expands Tax Capabilities with Addition of Partner David Morris in Salt Lake City
Foley & Lardner LLP announced today that David Morris has joined the firm’s Salt Lake City office as a partner in its Taxation Practice Group.
June 5, 2025
Press Releases
Foley Secures Top Rankings in Chambers USA 2025
Foley & Lardner LLP is proud to once again be recognized by Chambers & Partners as one of the leading law firms in the country in the 2025 edition of Chambers USA: America’s Leading Lawyers for Business.